Can manufacturing
keep up with demand for biologic
drugs?
Biologic drugs or “biologics” are therapeutic agents extracted or partially synthesized from biological sources, and the demand for them is growing.
This year alone 37% of the drugs the U.S. Food & Drug Administration approved have been biologics and they make up an estimated 70% of the top selling drugs in the marketplace.
Now, the manufacturers are facing a critical decision. Do they keep sailing the current course when it comes to production? Or do they seek out new ways to improve?